Bill Anderson, Roche pharma chief (David Paul Morris/Bloomberg via Getty Images)
July 21, 2022 10:21 AM EDTUpdated 03:19 PM
R&D

Roche trims out some pipeline fail­ures while flag­ging a PhI­II flop for Tecen­triq

John Carroll

Editor & Founder

Roche flagged a key set­back for its late-stage pipeline to­day, say­ing their IM­mo­tion010 kid­ney can­cer ad­ju­vant study of Tecen­triq has failed.

Roche phar­ma chief Bill …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

Re­gen­eron forges ahead in fac­tor XI de­spite field’s mixed re­sults

FDA re­jects Zealand Phar­ma's short bow­el syn­drome drug

Bris­tol My­ers pays $100M up­front to col­lab­o­rate with Leqem­bi orig­i­na­tor in Alzheimer's

In blow to com­pounders, FDA reaf­firms tirzepatide short­age is over

A service from the Financial Times